Zobrazeno 1 - 10
of 33
pro vyhledávání: ''
Autor:
Maria-Victoria Mateos, Jenna D. Goldberg, Ajai Chari, Arnob Banerjee, Lotfi Benboubker, Raluca Verona, Jeffrey R. Infante, Tara Stephenson, Jesús F. San-Miguel, Alfred L. Garfall, Yusri Elsayed, Manisha Bhutani, Hareth Nahi, Lionel Karlin, Niels W.C.J. van de Donk, Suzette Girgis, Saad Z. Usmani, Lixia Pei, Laura Rosiñol, Albert Oriol, Amrita Krishnan
Publikováno v:
The Lancet, 398(10301), 665-674. Elsevier Limited
Usmani, S Z, Garfall, A L, van de Donk, N W C J, Nahi, H, San-Miguel, J F, Oriol, A, Rosinol, L, Chari, A, Bhutani, M, Karlin, L, Benboubker, L, Pei, L, Verona, R, Girgis, S, Stephenson, T, Elsayed, Y, Infante, J, Goldberg, J D, Banerjee, A, Mateos, M-V & Krishnan, A 2021, ' Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study ', The Lancet, vol. 398, no. 10301, pp. 665-674 . https://doi.org/10.1016/S0140-6736(21)01338-6
LANCET
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Usmani, S Z, Garfall, A L, van de Donk, N W C J, Nahi, H, San-Miguel, J F, Oriol, A, Rosinol, L, Chari, A, Bhutani, M, Karlin, L, Benboubker, L, Pei, L, Verona, R, Girgis, S, Stephenson, T, Elsayed, Y, Infante, J, Goldberg, J D, Banerjee, A, Mateos, M-V & Krishnan, A 2021, ' Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study ', The Lancet, vol. 398, no. 10301, pp. 665-674 . https://doi.org/10.1016/S0140-6736(21)01338-6
LANCET
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Background There is a need for novel therapies for relapsed or refractory multiple myeloma, and B-cell maturation antigen (BCMA) is a validated target. Teclistamab is a bispecific antibody that binds BCMA and CD3 to redirect T cells to multiple myelo
Autor:
David C.W. Lau, Domenica Rubino, Kasper K Berthelsen, Michael T. Lund, Martin Kankam, Altynai Satylganova, Lone B Enebo
Publikováno v:
The Lancet. 397:1736-1748
Summary Background Cagrilintide, a long-acting amylin analogue, and semaglutide 2·4 mg, a glucagon-like peptide-1 analogue, are both being investigated as options for weight management. We aimed to determine the safety, tolerability, pharmacokinetic
Autor:
Stephen J. Rossi, Mary E. Rinella, Mark J. Jaros, Alex M. DePaoli, Marcelo Kugelmas, Stephen A. Harrison, Manal F. Abdelmalek, Hays Arnold, James F. Trotter, Mustafa R. Bashir, ing L, Angelo H. Paredes, Rohit Loomba
Publikováno v:
The Lancet. 391:1174-1185
Non-alcoholic steatohepatitis is a chronic liver disease characterised by the presence of hepatic steatosis, inflammation, and hepatocellular injury, for which no Food and Drug Administration (FDA)-approved treatment exists. FGF19 is a hormone that r
Autor:
Rupert W. Leong, Sudarshan Paramsothy, Hazel M. Mitchell, Michael A. Kamm, Watson Ng, Johan van den Bogaerde, Wei Xuan, Alissa Walsh, Enmoore Lin, Douglas Samuel, Ramesh Paramsothy, Nadeem O. Kaakoush, Thomas J. Borody, Susan J. Connor
Publikováno v:
The Lancet. 389:1218-1228
Summary Background The intestinal microbiota is implicated in the pathogenesis of ulcerative colitis. Faecal microbiota transplantation is a novel form of therapeutic microbial manipulation, but its efficacy in ulcerative colitis is uncertain. We aim
Autor:
Michael Huang, Adam Pavlicek, Ad C. van Nuenen, S.B. Willemse, Neeltje A. Kootstra, J. Marleen L. de Vree, F. Stelma, Janke Schinkel, Svend Rietdijk, Salah Hadi, P. Grint, Eva van der Veer, Meike H. van der Ree, S. Neben, Kai Liu, Richard Molenkamp, Jacqueline Blem, Marc van der Valk, Amy K Patick, John Grundy, Neil W. Gibson, Marten Harbers, Ulrich Beuers, Hendrik W. Reesink
Publikováno v:
The Lancet, 389(10070), 709-717. ELSEVIER SCIENCE INC
Lancet, 389(10070), 709-717. Elsevier Limited
Lancet, 389(10070), 709-717. Elsevier Limited
Summary Background miR-122 is an important host factor for hepatitis C virus (HCV) replication. The aim of this study was to assess the safety and tolerability, pharmacokinetics, and antiviral effect of a single dose of RG-101, a hepatocyte targeted
Autor:
Joseph L. Witztum, Rosie Z. Yu, Julian C. van Capelleveen, Mark J. Graham, Erik S.G. Stroes, Stanley T. Crooke, Sotirios Tsimikas, Rosanne M. Crooke, Nicholas J. Viney, Shuting Xia, Joseph A. Tami, Santica M. Marcovina, Richard S. Geary, Steven G. Hughes
Publikováno v:
Lancet, 388(10057), 2239-2253. Elsevier Limited
Summary Background Elevated lipoprotein(a) (Lp[a]) is a highly prevalent (around 20% of people) genetic risk factor for cardiovascular disease and calcific aortic valve stenosis, but no approved specific therapy exists to substantially lower Lp(a) co
Autor:
Catherine Dubos Arvis, Joo Hang Kim, Marcelo Garrido, Paul Baas, Margarita Majem, Gregory M. Lubiniecki, Mary J. Fidler, Marisa Dolled-Filhart, Gilberto de Castro, Enriqueta Felip, Yue Shentu, Julian R. Molina, Roy S. Herbst, Myung-Ju Ahn, Jose Luis Perez-Gracia, Dong Wan Kim, Edward B. Garon, Ji Youn Han, Ellie Im
Publikováno v:
LANCET
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Lancet, 387(10027), 1540-1550. Elsevier Limited
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Lancet, 387(10027), 1540-1550. Elsevier Limited
Background Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for progressive disease. We assessed the efficacy of pembrolizumab for patients with previously treated, PD-L1-p
Autor:
Vicki A. Morrison, Shmuel Shoham, Johan Maertens, John W. Baddley, Werner J. Heinz, Oliver A. Cornely, Dimitrios P. Kontoyiannis, Kieren A. Marr, Dong-Gun Lee, Thomas F. Patterson, Michael Giladi, Andrew J. Ullmann, Misun Lee, Mickael Aoun, Meinolf Karthaus, Galia Rahav, Dionysios Neofytos, Ilana Oren, Bernhardt Zeiher, Olivier Lortholary, Issam I Raad, Dominik Selleslag, Rochelle Maher, Eric J. Bow, Anne Schmitt-Hoffmann, George Richard Thompson, William W. Hope, Raoul Herbrecht
Publikováno v:
The Lancet. 387:760-769
Summary Background Isavuconazole is a novel triazole with broad-spectrum antifungal activity. The SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients with invasive mould disease. Methods This was a phase 3, doub
Autor:
Richard W. Joseph, Christine Mateus, Amita Patnaik, Roxana S. Dronca, Omid Hamid, Adil Daud, F. Stephen Hodi, Scot Ebbinghaus, Wen-Jen Hwu, Jeroen Elassaiss-Schaap, Peter D. Boasberg, Richard F. Kefford, Antoni Ribas, Tara C. Gangadhar, S. Peter Kang, Bartosz Chmielowski, Anthony M. Joshua, Jedd D. Wolchok, Caroline Robert, Kevin Gergich, Hassane M. Zarour, Xiaoyun Nicole Li, Robert Iannone, Michael A. Postow, Jeffrey S. Weber
Publikováno v:
The Lancet. 384:1109-1117
Summary Background The anti-programmed-death-receptor-1 (PD-1) antibody pembrolizumab has shown potent antitumour activity at different doses and schedules in patients with melanoma. We compared the efficacy and safety of pembrolizumab at doses of 2
Autor:
Ling Gao, Eldar Topuzov, Choondal Sivanandan, Chanchal Goswami, Charles S. Fuchs, Minori Koshiji, Astra M. Liepa, Joanna Pikiel, Bohuslav Melichar, Jonathan D. Schwartz, Ian Chau, Yanzhi Hsu, Cho Jae Yong, Mustapha Tehfe, John Zalcberg, Lucas Vieira dos Santos, Filip Dumitru, G. Aprile, David Ferry, Rodolfo Passalacqua, Josep Tabernero, Jiri Tomasek, William Campbell, Howard Safran
Publikováno v:
The Lancet. 383:31-39
Summary Background Vascular endothelial growth factor (VEGF) and VEGF receptor-2 (VEGFR-2)-mediated signalling and angiogenesis can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess whether ramucirumab, a monoclonal